Clinical trials: HER2 Negative Breast Cancer
Metastatic Breast Cancer
Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT)
This is a Phase II Randomized, Open Label, Non-comparative Trial (Parallel Assignment and Efficacy Study) for patients with HER-2 Negative Metastatic Breast Cancer Previously Treated With chemotherapy in the Neo-Adjuvant or…
- Trial name
- HIT (NCT00790894)
- Testing
- ixabepilone
- Where
- 13 sites in Greece
- Volunteers
- 64 people
- Sponsor
- Hellenic Cooperative Oncology Group
Adult Solid Neoplasm, Estrogen Receptor Negative
Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
This phase I trial studies the side effects and the best dose of cilengitide when given together with paclitaxel weekly in treating patients with solid tumors that have spread nearby or to other areas of the body and cannot be…
- Conditions
- Adult Solid Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma
- Trial name
- NCT01276496
- Testing
- Cilengitide, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Metastatic Breast Cancer
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
The purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with FGF aberrant metastatic breast cancer, as well as in the treatment of patients with biomarker negative (FGF…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, MBC, HER2 Positive
- Trial name
- NCT02202746
- Testing
- Lucitanib
- Where
- 33 sites in United States
- Volunteers
- 178 people
- Sponsor
- Clovis Oncology, Inc.
Breast Cancer
Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer
The purpose of this study is to identify new treatment regimens with better response rates and to find out if the combination of cisplatin and sorafenib followed by paclitaxel and sorafenib can shrink the size of your breast…
- Trial name
- NCT01194869
- Testing
- Sorafenib, Cisplatin, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Emory University
Breast Cancer
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
The scope of this study is to measure the impact of MammaPrint on treatment in Hormone Receptor (HR)-positive HER2-negative breast cancer patients.
- Trial name
- IMPACt (NCT02670577)
- Where
- 17 sites in United States
- Volunteers
- 481 people
- Sponsor
- Agendia
Breast Cancer, Invasive Breast Cancer
Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC
This study is investigational and is not designed to treat cancer. In other words, the study drug, entinostat, is not being given to treat cancer.
- Conditions
- Breast Cancer, Invasive Breast Cancer, ER-Negative PR-Negative HER2-Negative Breast Cancer
- Trial name
- NCT03361800
- Testing
- Entinostat
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
Doxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00960336
- Testing
- pegylated liposomal doxorubicin hydrochloride
- Where
- France
- Volunteers
- 59 people
- Sponsor
- ARCAGY/ GINECO GROUP
Breast Cancer
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
- Trial name
- BETH (NCT00625898)
- Testing
- Docetaxel, Trastuzumab, Carboplatin
- Where
- 649 sites in United States, Argentina and 38 more
- Volunteers
- 3,509 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
TOL2506A (OVELIA) is a Phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 in suppressing ovarian function in premenopausal women with HR+, HER2-negative breast cancer and men with HR+ breast cancer.
- Trial name
- NCT05645536
- Testing
- TOL2506, Tamoxifen, Letrozole tablets
- Where
- 46 sites in United States, Argentina and 4 more
- Volunteers
- 250 people
- Sponsor
- Tolmar Inc.
Advanced Breast Cancer
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
The purpose of this study is to assess the safety and efficacy of alpelisib plus fulvestrant in men and postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor 2 (HER2)-negative, advanced breast…
- Trial name
- NCT04524000
- Testing
- Alpelisib, Fulvestrant
- Where
- 15 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Advanced/Metastatic Solid Tumors
Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors
Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in…
- Trial name
- NCT04182516
- Testing
- NMS-03305293
- Where
- 10 sites in United States, Bulgaria and 3 more
- Volunteers
- 52 people
- Sponsor
- Nerviano Medical Sciences
Breast Cancer
Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer
The overall rationale of this study evaluating tolerance and efficacy of LY2780301 in combination with paclitaxel in HER2-negative, inoperable locally advanced or metastatic breast cancer (MBC) is based on : the medical need in…
- Trial name
- TAKTIC (NCT01980277)
- Testing
- LY2780301 + paclitaxel
- Where
- 2 sites in France
- Volunteers
- 68 people
- Sponsor
- Institut Paoli-Calmettes
HER2-negative Breast Cancer
Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer
The aim of this study is to investigate whether the application of concomitant modulated electro-hyperthermia in a neoadjuvant chemotherapeutic setting is beneficial for patients with HER2-negative, stage II-III breast cancer.
- Trial name
- NeoHTerMa (NCT05889390)
- Testing
- Oncotherm EHY-2030, Paclitaxel, Carboplatin
- Where
- Hungary
- Volunteers
- 71 people
- Sponsor
- Semmelweis University
Advanced HR+ HER2 Negative Breast Carcinoma
H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study
This study is a multi-center prospective real-world clinical study, mainly evaluating the efficacy and safety of H combined with CDK4/6 inhibitor + AI in the treatment of HR+/HER2+ advanced breast cancer; exploring potential…
- Trial name
- NCT05167643
- Testing
- Enituzumab injection+Abesili tablets+Anastrozole tablets
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
HER2-negative Breast Cancer Patients With Brain Metastases
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases.
- Trial name
- NCT06764940
- Testing
- Utidelone, Utidelone in combination with capecitabine
- Where
- 12 sites in United States
- Volunteers
- 120 people
- Sponsor
- Biostar Pharma, Inc.
Breast Cancer
A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel
To explore molecular biomarkers and/or gene expression signatures that predict response to bevacizumab given in combination with paclitaxel as first line therapy in HER2 negative metastatic breast cancer (MBC).
- Trial name
- BEVPAC (NCT01722968)
- Testing
- Bevacizumab, Paclitaxel
- Where
- Sweden
- Volunteers
- 33 people
- Sponsor
- Theodoros Foukakis
HER2-negative Breast Cancer, Inflammatory Breast Cancer
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
This phase I/II trial studies the side effects and best dose of romidepsin when given together with paclitaxel albumin-stabilized nanoparticle formulation and to see how well they work in treating patients with metastatic…
- Conditions
- HER2-negative Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01938833
- Testing
- Romidepsin, Abraxane
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Metastatic Breast Cancer
PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer
The purpose of this study is to decide the best dose of the study drug, PU-H71, that can be given in combination with the standard chemotherapy drug, nab-paclitaxel (Abraxane).
- Trial name
- NCT03166085
- Testing
- PU-H71, Nab-paclitaxel
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, HR+/HER2- Breast Cancer
QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
The goal of this clinical trial is to learn if QL1706 is effective in early HR+/HER2- breast cancer. It will also learn about the safety of QL1706.
- Trial name
- NCT06967103
- Testing
- QL1706, Nab-PE
- Where
- China
- Volunteers
- 238 people
- Sponsor
- Henan Cancer Hospital
HER2+ Breast Cancer
Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer
This study evaluated the clinical benefits of intravenous administration of pyrotinib combined with trastuzumab subcutaneous preparation by comparing the efficacy and quality of life of intravenous administration in the treatment…
- Trial name
- NCT06537674
- Testing
- Trastuzumab intravenous drip/Trastuzumab Subcutaneous Injection
- Volunteers
- 100 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.